Skinbac
Probiotical - Linkedin Probiotical - E-mail

PROBIAL BABY Flora

← Back to research page

Pediatrics

Developed Formulas
Benefits
  • Helps prevent pediatric diarrhea
  • Antipathogenic activity
  • Protects intestinal cells
Pediatrics
Ready to market
Pediatrics
Microbac
Pediatrics
In vitro test
Pediatrics
Allergen Free
Pediatrics
Real time stability
Pediatrics
Strain in oil
Components

Lacticaseibacillus rhamnosus LR04 (DSM 16605)
Bifidobacterium breve BR03 (DSM 16604)
Vitamin D3

Label Claim

(Europe): Vitamin D3, contributes to the normal function of immune system and to normal absorption/utilization of calcium and phosphorus.

Effective nutraceutical combination

Biotin
EFSA Claim: contributes to the mantainance of normal mucosa.

Scientific Rationale
In vitro studies

  • Lacticaseibacillus rhamnosus LR04 and Bifidobacterium breve BR03: In in vitro studies, these probiotic strains have demonstrated strong antipathogenic activity against various nosocomial pathogens and E. coli serotypes, which are common causes of diarrhea in infants [1,2]. LR04 has the capability to form a biofilm, protecting the strain from low pH environments and producing beneficial metabolites that support the health of mature enterocytes in the small intestine [3]. BR03 is noted for its strong anti-inflammatory properties and, in an in vivo study along with another B. breve strain, significantly counteracted the growth of Enterobacteriaceae isolated from colicky infants and reduced total fecal coliforms [4-8].

  • Vitamin D: Known primarily for its role in calcium homeostasis, vitamin D3 also possesses immunostimulating and immunomodulating activities. Additionally, it plays a critical role in the proper absorption of calcium and phosphorus, which are essential for the development of bones and brain function in children.

Bibliography

1. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32

2. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.  DOI: 10.35248/2329-8901.20.8.216

3. Chamignon C, et al. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains. Microorganisms. 2020 Jul 15;8(7):1053  doi: 10.3390/microorganisms8071053.

4.Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.

5. Bozzi Cionci N, et al. Therapeutic Microbiology: The Role of Bifidobacterium breve as Food Supplement for the Prevention/Treatment of Paediatric Diseases. Nutrients. 2018 Nov 10;10(11):1723. doi: 10.3390/nu10111723

6.  Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019;  7:214. Doi: 10.35248/2329-8901.19.7.214

7. Del Piano M., et al. In vitro sensitivity of probiotics to human pancreatic juice. J Clin Gastroenterol. 2008;42 Suppl 3 Pt 2:S170-S173. doi:10.1097/MCG.0b013e3181815976.

8. Mogna L. et al. Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014;48 Suppl 1:S37-S39. doi:10.1097/MCG.0000000000000234

Associations